Home Featured Page 176

Featured

Latest

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Psychedelic Research Bulletin: February 2022

PT298 – Michael Sapiro, PsyD – Vital Psychedelic Conversations

The Need for an International Psychedelic Religious Survey

Numinus Wellness Announces Voting Results From its Annual General and Special...

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Red Light Holland Reports Fiscal Third Quarter Results

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation...

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health...

PT297 – Laura Mae Northrup, LMFT – Radical Healership in a...

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies...

1...175176177...299 Page 176 of 299

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Psychedelic Research Bulletin: February 2022

PT298 – Michael Sapiro, PsyD – Vital Psychedelic Conversations

The Need for an International Psychedelic Religious Survey

Numinus Wellness Announces Voting Results From its Annual General and Special...

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Red Light Holland Reports Fiscal Third Quarter Results

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation...

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health...

PT297 – Laura Mae Northrup, LMFT – Radical Healership in a...

Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies...

EDITOR PICKS

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY